DOCSLIB.ORG

Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia Anouchka P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia Anouchka P Published OnlineFirst March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia Anouchka P. Laurent1,2, Aurelie Siret1, Cathy Ignacimouttou1, Kunjal Panchal3,M’Boyba Diop4, Silvia Jenni5, Yi-Chien Tsai5, Damien Roos-Weil1, Zakia Aid1, Nais Prade6, Stephanie Lagarde6, Damien Plassard7, Gaelle Pierron8, Estelle Daudigeos4, Yann Lecluse4, Nathalie Droin1, Beat C. Bornhauser5, Laurence C. Cheung3,9, John D. Crispino10, Muriel Gaudry1, Olivier A. Bernard1, Elizabeth Macintyre11, Carole Barin Bonnigal12, Rishi S. Kotecha3,9,13, Birgit Geoerger4, Paola Ballerini14, Jean-Pierre Bourquin5, Eric Delabesse6, Thomas Mercher1,15, and Sebastien Malinge1,3 ABSTRACT ◥ Purpose: Children with Down syndrome (constitutive trisomy RAS/MAPK pathway activation in our cohort of DS-ALL, as 21) that develop acute lymphoblastic leukemia (DS-ALL) have a well as in other pediatric B-ALL presenting somatic gain of the 3-fold increased likelihood of treatment-related mortality coupled chromosome 21 (B-ALLþ21). In murine and human B-cell with a higher cumulative incidence of relapse, compared with other precursors, activated KRASG12D functionally cooperates with children with B-cell acute lymphoblastic leukemia (B-ALL). This trisomy 21 to deregulate transcriptional networks that promote highlights the lack of suitable treatment for Down syndrome increased proliferation and self renewal, as well as B-cell differ- children with B-ALL. entiation blockade. Moreover, we revealed that inhibition of Experimental Design: To facilitate the translation of new ther- RAS/MAPK pathway activation using the MEK1/2 inhibitor apeutic agents into clinical trials, we built the first preclinical cohort trametinib decreased leukemia burden in several PDX models of patient-derived xenograft (PDX) models of DS-ALL, compre- of B-ALLþ21, and enhanced survival of DS-ALL PDX in com- hensively characterized at the genetic and transcriptomic levels, and bination with conventional chemotherapy agents such as vin- have proven its suitability for preclinical studies by assessing the cristine. efficacy of drug combination between the MEK inhibitor trametinib Conclusions: Altogether, using novel and suitable PDX mod- and conventional chemotherapy agents. els, this study indicates that RAS/MAPK pathway inhibition Results: Whole-exome and RNA-sequencing experiments represents a promising strategy to improve the outcome of Down revealed a high incidence of somatic alterations leading to syndrome children with B-cell precursor leukemia. mechanisms driving leukemia in DS-ALL, so that novel and more Introduction targeted treatments can be developed for these children. B-cell precursor acute lymphoblastic leukemia (B-ALL) is the most At the genetic level, apart from the constitutive trisomy 21, common type of childhood malignancy. Children with Down syn- DS-ALL presents a normal karyotype in more than 40% of cases, drome face a 27-fold increased risk to develop B-ALL (known as DS- and a lower incidence of ETV6-RUNX1 or high hyperdiploid (HeH) ALL; ref. 1), associated with a worse outcome and a significantly lower subtypes (2, 4). Half of DS-ALL samples overexpress cytokine event-free survival (EFS; 64% vs. 81%) and overall survival rate (OS; receptor-like factor 2 (CRLF2) either through microdeletions 74% vs. 89%) compared with other children (2). Treatment intensi- on chromosome X (P2RY8–CRLF2 fusion) or translocations to fication is limited in DS-ALL due to a higher therapy-related morbidity the IGH locus (5–7). JAK2-activating mutations, affecting the (TRM; 7% vs. 2%), ultimately leading to a higher rate of relapses (26% Arginine R683 residue located in the pseudokinase domain, are vs. 15%; refs. 2, 3). This emphasizes the need to better understand the also more frequently found in DS-ALL than in any other subgroups 1INSERM U1170, Gustave Roussy Institute, Universite Paris Saclay, Villejuif, Haematology, Oncology and Bone Marrow Transplantation, Perth Children's France. 2Universite Paris Diderot, Paris, France. 3Telethon Kids Cancer Centre, Hospital, Perth, Australia. 14Laboratoire d’Hematologie, Hopital^ Trousseau, Telethon Kids Institute, University of Western Australia, Perth, Australia. APHP, Paris-Sorbonne, Paris, France. 15Equipe Labellisee Ligue Nationale Contre 4Gustave Roussy Institute Cancer Campus, Department of Pediatric and Ado- le Cancer, Paris, France. lescent Oncology, INSERM U1015, Equipe Labellisee Ligue Nationale Contre le Note: Supplementary data for this article are available at Clinical Cancer Cancer, Universite Paris-Saclay, Villejuif, France. 5Department of Pediatric Research Online (http://clincancerres.aacrjournals.org/). Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland. 6Centre of Research on Cancer of Toulouse (CRCT), CHU Corresponding Author: Sebastien Malinge, Telethon Kids Institute, 15 Hospital Toulouse, Universite Toulouse III, Toulouse, France. 7IGBMC, Plateforme Geno- Avenue, Perth Children's Hospital, Nedlands, WA 6009, Australia. Phone: 61-8- mEast, UMR7104 CNRS, Ilkirch, France. 8Service de Gen etique, Institut Curie, 6319-1351; E-mail: [email protected] Paris, France. 9School of Pharmacy and Biomedical Sciences, Curtin University, – Bentley, Australia. 10Division of Hematology/Oncology, Northwestern Univer- Clin Cancer Res 2020;26:3307 18 11 sity, Chicago, Illinois. Hematology, Universite de Paris, Institut Necker-Enfants doi: 10.1158/1078-0432.CCR-19-3519 Malades and Assistance Publique–Hopitaux de Paris, Paris, France. 12Centre Hospitalier Universitaire de Tours, Tours, France. 13Department of Clinical Ó2020 American Association for Cancer Research. AACRJournals.org | 3307 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 Laurent et al. my 21 and the somatic alterations found in DS-ALL remain largely Translational Relevance unknown. B-cell precursor acute lymphoblastic leukemia (B-ALL) is the In this study, we showed that trisomy 21 functionally cooperates most common type of childhood malignancies, accounting for with constitutive activation of RAS/MAPK pathway in murine more than 20% of all pediatric cancers worldwide. Although and human B-cell precursors, indicating that disrupting this mech- survival rates have significantly improved, many children with anism may have a therapeutic impact for Down syndrome children B-ALL continue to have a poor prognosis, and suffer from with B-cell leukemia. We built a comprehensive and preclinical treatment-related toxicity and relapse, which are clinical features cohort of patient-derived xenograft (PDX) models, and show exemplified in Down syndrome children with acute lymphoblastic efficacy of MEK1/2 inhibition on human B-ALL samples harboring leukemia (known as DS-ALL). Among the most frequent somatic NRAS, KRAS, JAK2,andCBL mutations. Altogether, these results alterations seen in childhood B-ALL, gain of chromosome 21 (þ21) indicated that the RAS/MAPK inhibitor trametinib is therapeuti- and RAS/MAPK alterations are found in 30% to 40% and 50%, cally exploitable to improve the outcome of Down syndrome respectively. In this study, using DS-ALL as a paradigm, we children with B-ALL when combined with conventional chemo- showed that both events functionally cooperate and that treatment therapy agents. with the MEK inhibitor trametinib improved the survival in patient-derived xenograft models of childhood B-ALLþ21 with RAS-activating mutations. The comprehensive repository of Materials and Methods preclinical models developed here is of general relevance to inves- Human samples and sequencing tigate new targeted therapies in childhood leukemia. Human peripheral blood (PB) and bone marrow (BM) samples were collected from Trousseau, Necker, Tours and Toulouse hospitals (France), and Perth Children's Hospital (Australia). Nine samples were provided under the MAPPYACTS protocol (clinical trial.gov: of pediatric B-ALL (8, 9), suggesting an oncogenic cooperation NCT02613962). All human samples were obtained with the written between cytokine signaling activation and constitutive trisomy 21. or signed consent of the patient or parents/guardians. This study Other genetic alterations affecting NRAS, KRAS, IKZF1, PAX5,or conforms to the provisions of the Declaration of Helsinki, was CDKN2A/B genes are commonly found in DS- and non-DS B- approved by independent ethics committees, and complied to insti- ALL (10, 11). tutional, local, and national regulations. The development of DS-ALL models, from the transgenic Ts1Rhr Cells were subjected to Ficoll gradient and then either used fresh or mice [trisomic for the Down Syndrome Critical Region (DSCR); frozen in FBS with 10% DMSO. DNA and RNA were extracted using ref. 12], has highlighted the complexity of DS-ALL leukemogenesis RNA/DNA/Protein Purification Plus Kit (Norgen). Whole-exome in vivo (13). Indeed, four additional alterations affecting CRLF2, JAK2, sequencing (WES) libraries were prepared using SureSelect All Exon IKZF1, and PAX5 genes, added to trisomy 21, were required to drive a V5 Clinical Research Exome V1 or CREV2 Kits (Agilent). Sequencing B-ALL phenotype in this model. Moreover, the lack of cellular models was performed on a HiSeq2000 (Illumina) with a median
Load more

Recommended publications
  • Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia
    Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia Anouchka P. Laurent1,2, Aurélie Siret1, Cathy Ignacimouttou1, Kunjal Panchal3, M’Boyba K. Diop4, Silvia Jenny5, Yi-Chien Tsai5, Damien Ross-Weil1, Zakia Aid1, Naïs Prade6, Stéphanie Lagarde6, Damien Plassard7, Gaelle Pierron8, Estelle Daudigeos-Dubus4, Yann Lecluse4, Nathalie Droin1, Beat Bornhauser5, Laurence C. Cheung3,9, John D. Crispino10, Muriel Gaudry1, Olivier A. Bernard1, Elizabeth Macintyre11, Carole Barin Bonnigal12, Rishi S. Kotecha3,9,13, Birgit Geoerger4, Paola Ballerini14, Jean-Pierre Bourquin5, Eric Delabesse6, Thomas Mercher1,15 and Sébastien Malinge1,3 1INSERM U1170, Gustave Roussy Institute, Université Paris Saclay, Villejuif, France 2Université Paris Diderot, Paris, France 3Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia 4Gustave Roussy Institute Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Equipe Labellisée Ligue Nationale contre le Cancer, Université Paris-Saclay, Villejuif, France 5Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland 6Centre of Research on Cancer of Toulouse (CRCT), CHU Toulouse, Université Toulouse III, Toulouse, France 7IGBMC, Plateforme GenomEast, UMR7104 CNRS, Ilkirch, France 8Service de Génétique, Institut Curie, Paris, France 9School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia 10Division of Hematology/Oncology, Northwestern University, Chicago, USA 11Hematology, Université de Paris, Institut Necker-Enfants Malades and Assistance Publique – Hopitaux de Paris, Paris, France 12Centre Hospitalier Universitaire de Tours, Tours, France 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Genetic and Genomics Laboratory Tools and Approaches
    Genetic and Genomics Laboratory Tools and Approaches Meredith Yeager, PhD Cancer Genomics Research Laboratory Division of Cancer Epidemiology and Genetics [email protected] DCEG Radiation Epidemiology and Dosimetry Course 2019 www.dceg.cancer.gov/RadEpiCourse (Recent) history of genetics 2 Sequencing of the Human Genome Science 291, 1304-1351 (2001) 3 The Human Genome – 2019 • ~3.3 billion bases (A, C, G, T) • ~20,000 protein-coding genes, many non-coding RNAs (~2% of the genome) • Annotation ongoing – the initial sequencing in 2001 is still being refined, assembled and annotated, even now – hg38 • Variation (polymorphism) present within humans – Population-specific – Cosmopolitan 4 Types of polymorphisms . Single nucleotide polymorphisms (SNPs) . Common SNPs are defined as > 5% in at least one population . Abundant in genome (~50 million and counting) ATGGAACGA(G/C)AGGATA(T/A)TACGCACTATGAAG(C/A)CGGTGAGAGG . Repeats of DNA (long, short, complex, simple), insertions/deletions . A small fraction of SNPs and other types of variation are very or slightly deleterious and may contribute by themselves or with other genetic or environmental factors to a phenotype or disease 5 Different mutation rates at the nucleotide level Mutation type Mutation rate (per generation) Transition on a CpG 1.6X10-7 Transversion on a CpG 4.4X10-8 Transition: purine to purine Transition out of CpG 1.2X10-8 Transversion: purine to pyrimidine Transversion out of CpG 5.5X10-9 Substitution (average) 2.3X10-8 A and G are purines Insertion/deletion (average) 2.3X10-9 C and T are pyrimidines Mutation rate (average) 2.4X10-8 . Size of haploid genome : 3.3X109 nucleotides .
    [Show full text]
  • Longitudinal Exome-Wide Association Study to Identify Genetic Susceptibility Loci for Hypertension in a Japanese Population
    OPEN Experimental & Molecular Medicine (2017) 49, e409; doi:10.1038/emm.2017.209 Official journal of the Korean Society for Biochemistry and Molecular Biology www.nature.com/emm ORIGINAL ARTICLE Longitudinal exome-wide association study to identify genetic susceptibility loci for hypertension in a Japanese population Yoshiki Yasukochi1,2, Jun Sakuma2,3,4, Ichiro Takeuchi2,4,5, Kimihiko Kato1,6, Mitsutoshi Oguri1,7, Tetsuo Fujimaki8, Hideki Horibe9 and Yoshiji Yamada1,2 Genome-wide association studies have identified various genetic variants associated with complex disorders. However, these studies have commonly been conducted in a cross-sectional manner. Therefore, we performed a longitudinal exome-wide association study (EWAS) in a Japanese cohort. We aimed to identify genetic variants that confer susceptibility to hypertension using ~ 244 000 single-nucleotide variants (SNVs) and physiological data from 6026 Japanese individuals who underwent annual health check-ups for several years. After quality control, the association of hypertension with SNVs was tested using a generalized estimating equation model. Finally, our longitudinal EWAS detected seven hypertension-related SNVs that passed strict criteria. Among these variants, six SNVs were densely located at 12q24.1, and an East Asian-specific motif (haplotype) ‘CAAAA’ comprising five derived alleles was identified. Statistical analyses showed that the prevalence of hypertension in individuals with the East Asian-specific haplotype was significantly lower than that in individuals with the common haplotype ‘TGGGT’. Furthermore, individuals with the East Asian haplotype may be less susceptible to the adverse effects of smoking on hypertension. The longitudinal EWAS for the recessive model showed that a novel SNV, rs11917356 of COL6A5, was significantly associated with systolic blood pressure, and the derived allele at the SNV may have spread throughout East Asia in recent evolutionary time.
    [Show full text]
  • Kidney V-Atpase-Rich Cell Proteome Database
    A comprehensive list of the proteins that are expressed in V-ATPase-rich cells harvested from the kidneys based on the isolation by enzymatic digestion and fluorescence-activated cell sorting (FACS) from transgenic B1-EGFP mice, which express EGFP under the control of the promoter of the V-ATPase-B1 subunit. In these mice, type A and B intercalated cells and connecting segment principal cells of the kidney express EGFP. The protein identification was performed by LC-MS/MS using an LTQ tandem mass spectrometer (Thermo Fisher Scientific). For questions or comments please contact Sylvie Breton ([email protected]) or Mark A. Knepper ([email protected]).
    [Show full text]
  • Chromatin Conformation Links Distal Target Genes to CKD Loci
    BASIC RESEARCH www.jasn.org Chromatin Conformation Links Distal Target Genes to CKD Loci Maarten M. Brandt,1 Claartje A. Meddens,2,3 Laura Louzao-Martinez,4 Noortje A.M. van den Dungen,5,6 Nico R. Lansu,2,3,6 Edward E.S. Nieuwenhuis,2 Dirk J. Duncker,1 Marianne C. Verhaar,4 Jaap A. Joles,4 Michal Mokry,2,3,6 and Caroline Cheng1,4 1Experimental Cardiology, Department of Cardiology, Thoraxcenter Erasmus University Medical Center, Rotterdam, The Netherlands; and 2Department of Pediatrics, Wilhelmina Children’s Hospital, 3Regenerative Medicine Center Utrecht, Department of Pediatrics, 4Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, 5Department of Cardiology, Division Heart and Lungs, and 6Epigenomics Facility, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands ABSTRACT Genome-wide association studies (GWASs) have identified many genetic risk factors for CKD. However, linking common variants to genes that are causal for CKD etiology remains challenging. By adapting self-transcribing active regulatory region sequencing, we evaluated the effect of genetic variation on DNA regulatory elements (DREs). Variants in linkage with the CKD-associated single-nucleotide polymorphism rs11959928 were shown to affect DRE function, illustrating that genes regulated by DREs colocalizing with CKD-associated variation can be dysregulated and therefore, considered as CKD candidate genes. To identify target genes of these DREs, we used circular chro- mosome conformation capture (4C) sequencing on glomerular endothelial cells and renal tubular epithelial cells. Our 4C analyses revealed interactions of CKD-associated susceptibility regions with the transcriptional start sites of 304 target genes. Overlap with multiple databases confirmed that many of these target genes are involved in kidney homeostasis.
    [Show full text]
  • Cnvs Leading to Fusion Transcripts in Individuals with Autism Spectrum Disorder
    European Journal of Human Genetics (2012) 20, 1141–1147 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE CNVs leading to fusion transcripts in individuals with autism spectrum disorder Richard Holt1, Nuala H Sykes1, Ineˆs C Conceic¸a˜o2,3,4, Jean-Baptiste Cazier1, Richard JL Anney5, Guiomar Oliveira6,7,8, Louise Gallagher5, Astrid Vicente2,3,4, Anthony P Monaco1 and Alistair T Pagnamenta*,1 There is strong evidence that rare copy number variants (CNVs) have a role in susceptibility to autism spectrum disorders (ASDs). Much research has focused on how CNVs mediate a phenotypic effect by altering gene expression levels. We investigated an alternative mechanism whereby CNVs combine the 50 and 30 ends of two genes, creating a ‘fusion gene’. Any resulting mRNA with an open reading frame could potentially alter the phenotype via a gain-of-function mechanism. We examined 2382 and 3096 rare CNVs from 996 individuals with ASD and 1287 controls, respectively, for potential to generate fusion transcripts. There was no increased burden in individuals with ASD; 122/996 cases harbored at least one rare CNV of this type, compared with 179/1287 controls (P ¼ 0.89). There was also no difference in the overall frequency distribution between cases and controls. We examined specific examples of such CNVs nominated by case–control analysis and a candidate approach. Accordingly, a duplication involving REEP1-POLR1A (found in 3/996 cases and 0/1287 controls) and a single occurrence CNV involving KIAA0319-TDP2 were tested. However, no fusion transcripts were detected by RT-PCR.
    [Show full text]
  • Identification and Characterization of the Biochemical And
    IDENTIFICATION AND CHARACTERIZATION OF THE BIOCHEMICAL AND PHYSIOLOGICAL FUNCTIONS OF ACYL-COA DEHYDROGENASE 10 by Kaitlyn Nicole Kormanik BS Biology, Wilkes University, 2009 Submitted to the Graduate Faculty of Graduate School of Public Health in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2014 UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH This dissertation was presented by Kaitlyn Nicole Kormanik It was defended on April 17, 2014 and approved by Dissertation Director: Jerry Vockley, M.D. Ph.D., Professor Pediatrics, School of Medicine, Professor, Graduate School of Public Health, University of Pittsburgh Al-Walid Mohsen, Ph.D., Associate Professor, Pediatrics School of Medicine, University of Pittsburgh Candace Kammerer, Ph.D., Professor, Human Genetics Graduate School of Public Health, University of Pittsburgh Zsolt Urban, Ph.D., Associate Professor, Human Genetics Graduate School of Public Health, University of Pittsburgh David Finegold, Ph.D., Professor, Pediatrics School of Medicine, University of Pittsburgh ii Copyright © by Kaitlyn N. Kormanik 2014 iii IDENTIFICATION AND CHARACTERIZATION OF THE BIOCHEMICAL AND PHYSIOLOGICAL FUNCTIONS OF ACYL-COA DEHYDROGENASE 10 Kaitlyn Nicole Kormanik, PhD University of Pittsburgh, 2014 ABSTRACT The acyl-CoA dehydrogenase, ACAD, genes encode enzymes that are essential to cellular metabolism as evidenced by the identification in the past 20 years of genetic defects associated with nine members of this gene family. In total, these defects constitute the most common inborn errors of metabolism identified through newborn screening and so are concerns to public health. Recently, two new ACADs, ACAD10 and 11, of unknown function have been identified. This discovery raises the specter of additional unrecognized disorders since prior studies on these two ACADs suggested a novel role in metabolism.
    [Show full text]
  • Supplemental Data
    Supplementary Table 1. Gene sets from Figure 6. Lists of genes from each individual gene set defined in Figure 6, including the fold-change in expression of each gene in treatment group pair-wise comparisons. ENSEMBL: Ensembl gene identifier; Symbol: official gene symbol; logFC: log fold change; p value: significance of fold-change in a pair-wise comparison, P<0.05 cut-off; FDR: false discovery rate, expected proportion of false positives among the differentially expressed genes in a pair-wise comparison (FDR<0.25 cut-off). Sup. Table 1 SET I CP versus Sal CP versus CP+DCA DCA versus Sal ENSEMBL Symbol logFC PValue FDR logFC PValue FDR logFC PValue FDR Desc ENSMUSG00000020326 Ccng1 2.64 0.00 0.00 -0.06 0.13 0.96 0.40 0.00 0.23 cyclin G1 [Source:MGI Symbol;Acc:MGI:102890] ENSMUSG00000031886 Ces2e 3.97 0.00 0.00 -0.24 0.02 0.28 0.01 1.00 1.00 carboxylesterase 2E [Source:MGI Symbol;Acc:MGI:2443170] ENSMUSG00000041959 S100a10 2.31 0.00 0.00 -0.21 0.02 0.23 -0.11 0.53 1.00 S100 calcium binding protein A10 (calpactin) [Source:MGI Symbol;Acc:MGI:1339468] ENSMUSG00000092341 Malat1 1.09 0.00 0.00 -0.11 0.20 1.00 0.66 0.00 0.00 metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) [Source:MGI Symbol;Acc:MGI:1919539] ENSMUSG00000072949 Acot1 1.73 0.00 0.00 -0.22 0.01 0.12 -0.44 0.01 1.00 acyl-CoA thioesterase 1 [Source:MGI Symbol;Acc:MGI:1349396] ENSMUSG00000064339 mt-Rnr2 1.09 0.00 0.00 -0.08 0.17 1.00 0.67 0.00 0.07 mitochondrially encoded 16S rRNA [Source:MGI Symbol;Acc:MGI:102492] ENSMUSG00000025934 Gsta3 1.86 0.00 0.00 -0.28
    [Show full text]